Stabilization without Rituximab after Disease Activation in an Alemtuzumab-Treated Patient with Multiple Sclerosis and a Literature Overview

Step Status
Type: Enduring Material
Credit Hours: 1
Session Description: Series Title
Advanced Perspectives in MS: A Virtual Journal Club Series for the Advanced Practice Multiple Sclerosis Clinician

Due to the complex challenges presented by multiple sclerosis, the ever-changing landscape of treatment options, and the evolving nature of care trends for patients, it is vitally important that clinicians treating MS patients have access to the latest information available regarding the disease. Journal articles are a perfect example of the timely education that is required to keep pace with the current clinical environment. These articles are normally fairly brief, which allows busy practitioners to fit education into their schedule in manageable blocks of time. Additionally, research which is newly published in journals, typically contains the most up-to-date information available, eliminating the need to check for accuracy.

This enduring webinar will offer continuing education credits for physicians, PAs, nursing professionals, and pharmacists (if applicable) and will occur every other month for five sessions. Following the live broadcast, the event will be archived for one year.

Target Audience
This activity has been designed to meet the educational needs of physicians, PAs, nursing professionals, pharmacists, and other members of the healthcare team involved in the management of patients with MS.

Bryan D. Walker, MHS, PA-C, MSCS, Moderator

Duke University Medical Center
Durham, NC

Chantal Kahovec, NP, Author
Saskatoon Multiple Sclerosis Clinic
Saskatoon, SK Canada

Michael C. Levin, MD, FRCPC, FAAN, FANA, Author
Saskatoon Multiple Sclerosis Clinic
Saskatoon, SK Canada

Commercial Support Acknowledgment
This activity is supported by educational grants from Celgene Corporation, EMD Serono, Genentech, and Mallinckrodt Pharmaceuticals.

Learning Objectives: Upon completing this activity, participants should be better able to:
  • Identify the latest research and clinical information available in the literature with regard to MS diagnosis, treatment, and monitoring

  • Accreditation Statement
    In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Delaware Media Group. The CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Credit
    The CMSC designates this journal-based activity for a maximum of 1.00AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The Consortium of Multiple Sclerosis Centers designates this enduring material for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

    Nurse Credit
    The CMSC designates this enduring material for 1.00 contact hours (1.0 in the area of pharmacology).

    The Consortium of Multiple Sclerosis Centers (CMSC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education and will award 1 contact hours (.1 CEUs) to pharmacists who (1) complete the activity and (2) complete the evaluation form. The Universal Activity Number (UAN) for this activity is JA4008165-0000-19-008-H01-P. This is a knowledge-based activity.

    Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service. For information about CPE Monitor, visit

    Certificate of Participation for Other Healthcare Professionals
    A Certificate of Participation will be given upon completion of course requirements enabling participants to register their credit with the appropriate licensing boards or associations. Participants may apply for other accreditations using procedures established by specific organizations.

    Disclosure of Financial Relationships
    In accordance with the ACCME Standards for Commercial Support, CMSC requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. CMSC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC seeks to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC is committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.

    Faculty Disclosures
    The program faculty reported the following relevant financial relationships that they have with commercial interests:

    Chantal Kahovec, NP has disclosed no relevant financial relationships.

    Michael C. Levin, MD, FRCPC, FAAN, FANA has disclosed no relevant financial relationships.

    Bryan D. Walker, MHS, PA-C, MSCS (Planner) has disclosed the following relevant financial relationships: Consulting Fees: Biogen, EMD Serono, Novartis, and Sanofi-Genzyme; Speakers Bureau: Biogen.

    John F. Kramer, PA-C (Planner) has disclosed the following relevant financial relationships: Consulting Fees: Biogen, EMD Serono, and Novartis Pharmaceuticals; Speakers Bureau: Alexion, Biogen, EMD Serono, and Genentech.

    Staff Disclosures
    The planners, reviewers, editors, staff, or other members at CMSC who are in a position to control content have declared that they have no relevant financial relationships.

    Disclosure of Unlabeled Use
    CMSC requires faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

    CMSC presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC and the commercial supporters assume no liability for the information herein.

    Method of Participation / How to Receive Credit
    To successfully complete this activity, the participant must review the accreditation information, including learning objectives and faculty disclosures, view the webinar, complete the evaluation and claim credit.

    Technical Requirements
    This activity is best viewed using the most up to date version of Google Chrome, FireFox, or Microsoft Edge.
    There is no fee to participate in this activity.

    Privacy Policy
    To view the CMSC Privacy Policy, visit our website at

    Credit Types

    AAPA:  1.00
    ACPE:  1.00
    CME:  1.00
    CNE:  1.00
    CNE - Pharmacology:  1.00
    Letter of Completion:  1.00


    Connect on Facebook LinkedIn RSS twitter